BIT Capital GmbH lessened its holdings in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) by 86.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 31,830 shares of the company's stock after selling 199,373 shares during the period. BIT Capital GmbH's holdings in Verona Pharma were worth $1,478,000 at the end of the most recent reporting period.
Other large investors have also recently made changes to their positions in the company. Maverick Capital Ltd. boosted its stake in shares of Verona Pharma by 36.3% during the third quarter. Maverick Capital Ltd. now owns 4,215,973 shares of the company's stock worth $121,294,000 after buying an additional 1,123,166 shares during the period. Frazier Life Sciences Management L.P. increased its position in Verona Pharma by 2.1% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 3,383,950 shares of the company's stock worth $97,356,000 after purchasing an additional 69,601 shares in the last quarter. Eventide Asset Management LLC lifted its stake in shares of Verona Pharma by 359.6% during the 3rd quarter. Eventide Asset Management LLC now owns 2,425,846 shares of the company's stock worth $69,792,000 after purchasing an additional 1,898,065 shares during the period. Jennison Associates LLC boosted its stake in Verona Pharma by 8.5% in the 4th quarter. Jennison Associates LLC now owns 1,889,542 shares of the company's stock worth $87,750,000 after buying an additional 148,656 shares during the last quarter. Finally, Wellington Management Group LLP boosted its holdings in Verona Pharma by 19.6% in the third quarter. Wellington Management Group LLP now owns 1,878,632 shares of the company's stock valued at $54,048,000 after acquiring an additional 307,272 shares during the last quarter. 85.88% of the stock is owned by institutional investors and hedge funds.
Verona Pharma Price Performance
NASDAQ:VRNA traded down $0.41 during mid-day trading on Monday, hitting $62.29. The company's stock had a trading volume of 468,475 shares, compared to its average volume of 1,426,595. The stock has a fifty day moving average of $62.20 and a 200-day moving average of $46.50. The company has a current ratio of 13.03, a quick ratio of 12.88 and a debt-to-equity ratio of 0.93. The company has a market capitalization of $5.03 billion, a price-to-earnings ratio of -32.33 and a beta of 0.39. Verona Pharma plc has a fifty-two week low of $11.39 and a fifty-two week high of $70.40.
Insiders Place Their Bets
In other Verona Pharma news, insider Kathleen A. Rickard sold 79,264 shares of the business's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $8.35, for a total value of $661,854.40. Following the transaction, the insider now owns 2,608,976 shares of the company's stock, valued at approximately $21,784,949.60. The trade was a 2.95 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 4.80% of the company's stock.
Wall Street Analyst Weigh In
Several analysts recently issued reports on VRNA shares. Roth Mkm initiated coverage on Verona Pharma in a report on Friday, January 10th. They issued a "buy" rating and a $68.00 price target for the company. Truist Financial restated a "buy" rating and issued a $57.00 target price (up from $44.00) on shares of Verona Pharma in a research note on Wednesday, January 8th. HC Wainwright increased their price target on Verona Pharma from $60.00 to $75.00 and gave the company a "buy" rating in a report on Friday, February 28th. Canaccord Genuity Group lifted their price objective on Verona Pharma from $44.00 to $72.00 and gave the stock a "buy" rating in a report on Wednesday, February 12th. Finally, Wells Fargo & Company upped their price target on shares of Verona Pharma from $74.00 to $93.00 and gave the company an "overweight" rating in a report on Friday, February 28th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $69.14.
Get Our Latest Stock Analysis on Verona Pharma
Verona Pharma Profile
(
Free Report)
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
Recommended Stories
Before you consider Verona Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verona Pharma wasn't on the list.
While Verona Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
